Abstract
Objectives To assess the transmission dynamics and the health systems’ burden of COVID-19 using an Agent Based Modeling (ABM) approach using a synthetic population.
Study design The study used a synthetic population with 31,738,240 agents representing 90.67 percent of the overall population of Telangana state, India as per 2011 Census of India. Lockdown phases as per Indian scenario considering the effects of post-lockdown, use of control measures and immunity on secondary infections were studied.
Methods The counts of people in different health states were measured separately for each district of Telangana. The model was run for 365 days and six scenarios with varying proportions of people using control measures (100%, 75% and 50%) and varying immunity periods (90 and 180 days). Sensitivity Analysis has been done for two districts to compare the change in transmission dynamics when incubation period and asymptomatic proportion are changed.
Results Results indicate that the peak values were attained soon after the lockdown was lifted. The risk estimates indicate that protection factor values are higher when more proportion of people adopt control measures.
Conclusions ABM approach helps to analyze grassroot details compared to compartmental models. Risk estimates allow the policymakers to determine the protection offered, its strength and percentage of population shielded by use of control measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This is an unfunded research activity.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Python code and detailed resutls have all been provided in the below link.
https://osf.io/3nxby/?view_only=96320e1dd7f048318294898ccd657275
